Sinsin Pharmaceutical Co., Ltd (KOSDAQ:002800)
South Korea
· Delayed Price · Currency is KRW 6,030.00
-50.00 (-0.82%)
At close: Apr 28, 2026
Sinsin Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 113,778 | 106,388 | 102,586 | 91,926 | 74,008 | Upgrade
|
| Other Revenue | - | -0 | -0 | - | -0 | Upgrade
|
| Revenue | 113,778 | 106,388 | 102,586 | 91,926 | 74,008 | Upgrade
|
| Revenue Growth (YoY) | 6.95% | 3.71% | 11.60% | 24.21% | 10.25% | Upgrade
|
| Cost of Revenue | 70,769 | 70,278 | 69,274 | 61,706 | 52,318 | Upgrade
|
| Gross Profit | 43,009 | 36,110 | 33,312 | 30,220 | 21,689 | Upgrade
|
| Selling, General & Admin | 30,054 | 27,385 | 25,726 | 23,770 | 21,277 | Upgrade
|
| Research & Development | 898.01 | 474.5 | 488.03 | 89.9 | 709.07 | Upgrade
|
| Amortization of Goodwill & Intangibles | 17.15 | 15.79 | 14.09 | 9.43 | - | Upgrade
|
| Other Operating Expenses | 270.39 | 240.35 | 220.94 | 228.42 | 220.21 | Upgrade
|
| Operating Expenses | 32,219 | 29,220 | 27,308 | 24,794 | 23,032 | Upgrade
|
| Operating Income | 10,790 | 6,890 | 6,004 | 5,426 | -1,343 | Upgrade
|
| Interest Expense | -1,636 | -1,960 | -1,937 | -1,481 | -963.24 | Upgrade
|
| Interest & Investment Income | 31.04 | 37.83 | 40.34 | 8.3 | 2 | Upgrade
|
| Currency Exchange Gain (Loss) | -138.14 | 404.45 | 19.14 | 277.35 | 242.67 | Upgrade
|
| Other Non Operating Income (Expenses) | 586.64 | 84.44 | -131.88 | -222.32 | 331.37 | Upgrade
|
| EBT Excluding Unusual Items | 9,634 | 5,457 | 3,995 | 4,009 | -1,730 | Upgrade
|
| Gain (Loss) on Sale of Investments | 138.96 | -323.41 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 36.35 | 7 | -0 | 38.55 | 0.73 | Upgrade
|
| Asset Writedown | - | - | - | - | -18.16 | Upgrade
|
| Pretax Income | 9,809 | 5,141 | 3,995 | 4,047 | -1,747 | Upgrade
|
| Income Tax Expense | 526.37 | 329.15 | -651.57 | -308.12 | -297.73 | Upgrade
|
| Earnings From Continuing Operations | 9,282 | 4,811 | 4,646 | 4,355 | -1,449 | Upgrade
|
| Minority Interest in Earnings | 9.52 | 77.05 | 33.77 | 59.32 | -26.47 | Upgrade
|
| Net Income | 9,292 | 4,888 | 4,680 | 4,415 | -1,476 | Upgrade
|
| Net Income to Common | 9,292 | 4,888 | 4,680 | 4,415 | -1,476 | Upgrade
|
| Net Income Growth | 90.08% | 4.46% | 6.01% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| Shares Change (YoY) | -0.15% | 0.07% | - | - | - | Upgrade
|
| EPS (Basic) | 613.00 | 322.00 | 308.49 | 291.00 | -97.29 | Upgrade
|
| EPS (Diluted) | 613.00 | 322.00 | 308.49 | 291.00 | -97.29 | Upgrade
|
| EPS Growth | 90.37% | 4.38% | 6.01% | - | - | Upgrade
|
| Free Cash Flow | 6,971 | 4,439 | -1,081 | 4,553 | -2,659 | Upgrade
|
| Free Cash Flow Per Share | 459.90 | 292.38 | -71.27 | 300.15 | -175.28 | Upgrade
|
| Gross Margin | 37.80% | 33.94% | 32.47% | 32.87% | 29.31% | Upgrade
|
| Operating Margin | 9.48% | 6.48% | 5.85% | 5.90% | -1.81% | Upgrade
|
| Profit Margin | 8.17% | 4.59% | 4.56% | 4.80% | -1.99% | Upgrade
|
| Free Cash Flow Margin | 6.13% | 4.17% | -1.05% | 4.95% | -3.59% | Upgrade
|
| EBITDA | 14,942 | 11,150 | 9,941 | 9,184 | 2,329 | Upgrade
|
| EBITDA Margin | 13.13% | 10.48% | 9.69% | 9.99% | 3.15% | Upgrade
|
| D&A For EBITDA | 4,152 | 4,260 | 3,937 | 3,758 | 3,672 | Upgrade
|
| EBIT | 10,790 | 6,890 | 6,004 | 5,426 | -1,343 | Upgrade
|
| EBIT Margin | 9.48% | 6.48% | 5.85% | 5.90% | -1.81% | Upgrade
|
| Effective Tax Rate | 5.37% | 6.40% | - | - | - | Upgrade
|
| Advertising Expenses | 4,366 | 4,207 | 4,340 | 4,188 | 3,417 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.